Proactive Investors - Run By Investors For Investors

Supreme Pharmaceuticals Inc makes first MMPR revenue

Supreme provided the group with six strains for production and future sale to the producer's registered clients.
A high-tech growing facility.
“The genetics business diversifies our revenue while remaining committed to supporting the aggregate growth of the legal cannabis industry in Canada," Fowler has said.

Supreme Pharmaceuticals Inc (CSE:SL) has made its first MMPR (marijuana for medical purposes regulations) revenue, it told investors.

The Canada-listed group has completed its first sale of cannabis genetics to another Canadian licensed producer (LP), it told investors.

Supreme provided the group with six strains for production and future sale to the producer's registered clients.

Supreme chief executive John Fowler said: "We believe strongly in the importance of good genetics to produce medical cannabis that is high quality, desirable in the marketplace and economical for the producer.

"I am very proud of my team for identifying and executing on this revenue opportunity, well in advance of obtaining our sales licence for dried marijuana."

In May, the group announced the start of its business-to-business sales model by entering into letters of intent for the sale of dried marijuana to five fully licensed Canadian licensed producers and this marks the commencement of the second leg of the group's business.

“The genetics business diversifies our revenue while remaining committed to supporting the aggregate growth of the legal cannabis industry in Canada," Fowler has said.

It's been a busy week for the firm, having raised C$3.62mln from a share and a warrant issue to expand its Kincardine greenhouse facility after strong demand  for its medical-use marijuana.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Scientist conducting work
Sun
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use